FDA issues a Drug Safety Communication announcing a class-wide labeling change for benzodiazepines to include the risks of abuse, misuse, addiction, physical dependence and withdrawal reactions to help improve their safe use.
Read more: FDA Requiring Labeling Changes for Benzodiazepines